fever; pain in eyes; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 17Mar2021 15:00 (Lot number: EP1534) at the age of 62 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Autonomic dysfunction" (ongoing), notes: Onset Date: age 24; "Hashimoto's" (ongoing), notes: Onset Date: age 26, 2nd vaccine; "Antiphospholipid proteine syndrome" (ongoing), notes: Onset Date: age 20; "myasthenia gravis", start date: 2017 (ongoing), notes: Onset Date: 2017; "stiff person syndrome", start date: 2018 (ongoing), notes: Onset Date: 2018. Family history included: "Sjogren's" (ongoing), notes: Onset Date: age 20, Sjogren's had never been seen enough to damage my eyes till after 2nd vaccine; "CLL notactive", start date: 2015 (ongoing), notes: Onset Date: 2015. Concomitant medication(s) included: IVIGLOB-EX taken for autoimmune disorder, start date: 10Mar2021, stop date: 12Mar2021; RITUXAN taken for autoimmune disorder, start date: 07Jan2021, stop date: 07Jan2021. Vaccination history included: Bnt162b2 (Dose 1, Date: 24Feb2021 03:00, Anatomical location: right arm, Route of administration: Intramuscular, Lot: E19265), administration date: 24Feb2021, for Covid-19 immunization, reaction(s): "Severe pain", "Fever", "Pain in head, hands, knees, ankle, feet, and back", "Pain in head, hands, knees, ankle, feet, and back", "Pain in head, hands, knees, ankle, feet, and back", "Pain in head, hands, knees, ankle, feet, and back", "Pain in head, hands, knees, ankle, feet, and back", "Dry eyes", "painful eye", "Dry Mouth", "Can't open eyes due to swelling". The following information was reported: PYREXIA (medically significant) with onset 18Mar2021 03:00, outcome "recovered" (Mar2021), described as "fever"; EYE PAIN (non-serious) with onset 18Mar2021 03:00, outcome "not recovered", described as "pain in eyes". The patient underwent the following laboratory tests and procedures: alanine aminotransferase (6.0-29): (unspecified date) normal, notes: 33 Normal 0-32; (11Aug2021) 45, notes: Routine blood work; antibody test: (unspecified date) 0.9, notes: 2.9 Normal; aspartate aminotransferase: (10Sep2021) 53; (14Sep2021) 41, notes: 1st day d x COVID; bacterial test: (unspecified date) rare; blood glucose: (02Aug2021) normal, notes: 127 Normal 05.99; blood test: (11Aug2021) unknown results; blood urea (12-20): (14Sep2021) 11, notes: 1st day d x COVID; c3 glomerulopathy (82-167): (10Aug2021) 170, notes: 170 normal 82-167; carbon dioxide: (unspecified date) normal, notes: 18 normal 20-29; chest x-ray: (14Sep2021) unknown results, notes: Patchy bilateral ground glass infiltrates-atypical pneumonia; c-reactive protein: (unspecified date) normal, notes: 39 Normal 0-10; c-reactive protein (0-1): (14Sep2021) 4.2, notes: 1st day d x COVID; oxygen saturation (22-30): (10Sep2021) 21, notes: 1st day of symptoms COVID; protein total (0.3-8.2): (14Sep2021) 0.4, notes: 1st day d x COVID; red blood cell count: (11Aug2021) unknown results; specific gravity urine: (unspecified date) normal, notes: 1024 Normal 1.008-1.022; urinary sediment present: (unspecified date) normal, notes: 15 Normal 0-2; (unspecified date) normal, notes: 0.2; urine analysis: (11Aug2021) 0.2, notes: 4 Normal; (10Sep2021) unknown, notes: Color Hazy; (01Aug2021) unknown results. Therapeutic measures were taken as a result of eye pain and treatment included with Meloxicam that was not helping.  Clinical course- The patient stated for the treatment of fever that patient still do not know what to do about eye pain dryness and for the treatment of pain Meloxicam was not helping.